ArticleFrontiers in oncology2025
Prognostic implications of autophagy and pyroptosis related genes in oral squamous cell carcinoma: research on bioinformatics and experiments.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cannabinoid Signaling and Autophagy in Oral Disease: Molecular Mechanisms and Therapeutic Implications.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Oral squamous cell carcinoma (OSCC) is associated with poor prognosis, underscoring the urgent need to identify biomarkers that can predict patient outcomes and guide personalized treatment strategies. This study analyzes the prognostic potential of autophagy and pyroptosis-related genes in OSCC by bioinformatics approaches. Methods: Clinical data and gene expression profiles for OSCC were obtained from the TCGA database, while autophagy and pyroptosis-related genes were retrieved from the GeneCards database. A prognostic model based on these genes was constructed using the LASSO Cox regression method. The performance of the model was evaluated through ROC curve analysis and survival analysis. Gene set enrichment analysis (GSEA) was performed to explore the functional pathways associated with these genes, and immune infiltration was assessed through immune profiling. The independent prognostic value of the genes included in the model was evaluated using multivariate Cox regression and nomogram analyses. Results: Eight autophagy and pyroptosis-related genes (BAK1, ATG5, VEGFA, GABARAPL1, RSL1D1, CYCS, TOMM20, and PGAM5) were found to have significantly lower overall survival (OS) in the high-expression group compared to the low-expression group in OSCC tissues. GSEA revealed that these genes were involved in pathways such as the Initial Triggering of Complement, the Role of Phospholipids in Phagocytosis, CD22-Mediated BCR Regulation, and the Role of Lat2/NATL/LAB in Calcium Mobilization. Furthermore, BAK1 and GABARAPL1 were positively correlated with immune cell infiltration in OSCC, while the other six genes showed negative correlations with immune infiltration. Notably, BAK1 and GABARAPL1 were identified as independent prognostic factors for OSCC, with BAK1 showing particularly strong diagnostic predictive potential. Functional assays revealed that silencing BAK1 in OSCC cell lines (SCC-15 and CAL-27) significantly inhibited cell proliferation and migration Conclusions: Our findings suggest that the high expression of eight autophagy and pyroptosis-related genes in OSCC correlates with poor prognosis. In particular, BAK1 emerges as an independent prognostic marker with high diagnostic potential. These results offer promising insights into the development of gene-targeted therapies for OSCC, with BAK1 representing a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.